We are live on ! Find out more
PHXM

PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM

Delisted

PHXM was delisted on the 8th of March, 2024.

Back to rankings
 

About: Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Its ERYCAPS platform, uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its lead product candidate eryaspase, also referred as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing eryaspase for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple negative breast cancer, or TNBC.

Employees: 49

Healthcare Drug Manufacturers - General

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 0%
Negative 0%
Neutral
GlobeNewsWire
2 years ago
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
Neutral
GlobeNewsWire
2 years ago
PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024
Lyon (France) and Cambridge (MA, US), January 18, 2024, at 10:05pm CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces its cash position as of December 31, 2023, and its financial calendar for 2024.
PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024
Neutral
Seeking Alpha
2 years ago
PHAXIAM Therapeutics S.A. (PHXM) Q3 2023 Earnings Call Transcript
PHAXIAM Therapeutics S.A. (NASDAQ:PHXM ) Q3 2023 Earnings Conference Call November 15, 2023 8:30 AM ET Company Participants Thibaut Fayet - CEO Pascal Birman - CMO Eric Soyer - CFO Conference Call Participants Operator Good day, and welcome to the PHAXIAM Therapeutics Business Update and Financial Highlights of Q3 2023.
Neutral
GlobeNewsWire
2 years ago
PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023
Conference call and webcast (English) on Wednesday, November 15, 2023 at 8:30am ET / 2:30pm CET Ambitious clinical development strategy progressing to create a global phage therapy leader in high-value indications Early access program continues to gain momentum with the treatment of more than 90 patients suffering from severe and resistant infection prosthetic joint infections of the hip or knee (PJI) Cash and cash equivalents of €15.6 million ($16.5 million) as of September 30, 2023 Lyon (France) et Cambridge (MA, US), November 14, 2023, at 10:05pm CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today provides a business and financial update for the third quarter of 2023. “The third quarter of 2023 was a prolific period during which we managed to move forward with our development programs and benefited from the complementarities of our teams in the context of the merger completion” stated Thibaut du Fayet, Chief Executive Officer of PHAXIAM Therapeutics.
PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023
See News Rankings
Price charts implemented using Lightweight Charts™